OIPE TO BE THE PER 1 2 2007

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known			
				Application Number	10/590,311		
INFORMATION DISCLOSURE				Filing Date	August 23, 2006	ust 23, 2006	
S	STATEMENT BY APPLICANT			First Named Inventor	Francisco Javier Vila PAHI et al.		
				Art Unit	Net-Yet-Assigned 1623	٦	
	(Use as many sheets as necessary)			Examiner Name	Mot Yet Assigned Ganapat	h	
Sheet	1	of	1	Attorney Docket Number	68970-235077		

/ Krishnan

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA					
	AB					

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
	BA						
	BB						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nich indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
/G.K.	CA	JORDAN, K.M. et al., "EULAR Recommendations 2003: An Evidence Based Approach to the Management of Knee Osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT); Ann Rheum Dis. 2003; 62, 1145-1155.			
/G.K./		ALTMAN, R. et al., "Development of Criteria for the Classification and Reporting of Osteoarthritis", <i>Arthritis and Rheumatism</i> , Vol. 29, No. 8, August 1986, pp. 1039-1049.			
/G.K./	CC	KLIPPEL, John H. et al., "Osteoarthritis and Related Disorders", PHEUMATOLOGY, 2 ND Ed.,			
/G.K./	CD	LEQUESNE, M., "Symptomatic Slow-Acting Drugs in Osteoarthritis: A Novel Therapeutic Concept?*", Expansion Scientifique Française, 1994, 69-73.			
/G.K./	CE	HARRIS, Edward D., RHEUMATOID ARTHRITIS, "Pathophysiology and Implications of Therapy", <i>The New England Journal of Medicine</i> , Vol. 322, No. 18, May 3, 1990, pps. 1277-1289.			
/G.K./		HOCHBERG, Marc C., "Adult and Juvenile Rheumatoid Arthritis: Current Epidemiologic Concepts", EPIDEMIOLOGIC REVIEWS - THE JOHNS HOPKINS UNIVERSITY SCHOOL OF HYGIENE AND PUBLIC HEALTH, Vol. 3, 1981, pp. 27-44.			
/G.K./	CG	Committee for Proprietary Medicinal Products (CPMP), "Points to Consider on Clinical Investigation of Medicinal Products Other than NSAIDS for Treatment of Rheumatoid Arthritis", The European Agency for the Evaluation for Medicinal Products, London, December 17, 2003.			
/G.K./	СН	COMBE, Bernard et al., "Eular Recommendations for the Management of Early Arthritis: Report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)", <i>Ann Rheum Dis.</i> , ARD Online First, published January 5, 2006, www.ard.bmjjournals.com , pps. 1-24.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

	-		
Examiner	/Gananathy Krishnan/	Date	04/22/2008
Signature	/Фанаранну Кибинан/	Considered	